...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Musculoskeletal Disorders >Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study
【24h】

Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

机译：特立帕肽有效治疗骨质疏松症与绝经后骨质疏松妇女的生活质量提高相关：欧洲Forsteo观察研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background To describe changes in health-related quality of life (HRQoL) of postmenopausal women with osteoporosis treated with teriparatide for up to 18 months and followed-up for a further 18 months, and to assess the influence of recent prior and incident fractures. Methods The European Forsteo Observational Study (EFOS) is an observational, prospective, multinational study measuring HRQoL using the EQ-5D. The primary objective was to assess changes in HRQoL during 36 months in the whole study population. A secondary post-hoc analysis examined fracture impact on HRQoL in four subgroups classified based on recent prior fracture 12 months before baseline and incident clinical fractures during the study. Changes from baseline were analysed using a repeated measures model. Results Of the 1581 patients, 48.4% had a recent prior fracture and 15.6% of these patients had an incident fracture during follow-up. 10.9% of the 816 patients with no recent prior fracture had an incident fracture. Baseline mean EQ-VAS scores were similar across the subgroups. In the total study cohort (n?=?1581), HRQoL (EQ-VAS and EQ-5D index scores) improved significantly from baseline to 18 months and this improvement was maintained over the 18-month post-teriparatide period. Improvements were seen across all five EQ-5D domains during teriparatide treatment that were maintained after teriparatide was discontinued. Subjects with incident clinical fractures had significantly less improvement in EQ-VAS than those without incident fractures. Recent prior fracture did not influence the change in EQ-VAS during treatment. Conclusions EFOS is the first longitudinal study in women with severe postmenopausal osteoporosis in the real world setting to show a substantial improvement in HRQoL during teriparatide treatment that was sustained during subsequent treatment with other medications. The increase in HRQoL was lower in the subgroups with incident fracture but was not influenced by recent prior fracture. The results should be interpreted in the context of the design of an observational study.
机译：背景技术描述接受特立帕肽治疗长达18个月，随访18个月的绝经后骨质疏松妇女的健康相关生活质量（HRQoL）的变化，并评估近期骨折和近期骨折的影响。方法欧洲Forsteo观察研究（EFOS）是一项观察性，前瞻性，跨国研究，使用EQ-5D测量HRQoL。主要目标是评估整个研究人群在36个月内HRQoL的变化。事后的第二次分析分析了骨折对四个子组的HRQoL的影响，这些子组根据基线之前12个月的近期骨折和研究期间发生的临床骨折进行分类。使用重复测量模型分析了自基线的变化。结果在1581例患者中，有48.4％曾有近期骨折，其中15.6％的患者在随访期间发生了骨折。在816例近期没有骨折的患者中，有10.9％发生了骨折。各亚组的基线平均EQ-VAS得分相似。在整个研究队列中（n = 1581），HRQoL（EQ-VAS和EQ-5D指数评分）从基线到18个月显着改善，并且这种改善在特立哌肽治疗后的18个月中一直保持。终止特立帕肽治疗后，在特立帕肽治疗期间所有五个EQ-5D结构域均出现了改善。发生临床骨折的受试者与未发生骨折的受试者相比，EQ-VAS的改善明显较少。最近的先前骨折并未影响治疗期间EQ-VAS的变化。结论EFOS是在现实世界中对严重绝经后骨质疏松症妇女进行的第一项纵向研究，显示在特立帕肽治疗期间HRQoL有了实质性改善，并在随后的其他药物治疗中持续改善。 HRQoL的增加在发生骨折的亚组中较低，但不受近期骨折的影响。应在观察性研究的设计背景下解释结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号